Navigation Links
K-V Pharmaceutical Secures Financing Commitments Establishing Path Forward For Specialty Pharmaceutical Business
Date:11/17/2010

esults or outcomes to differ materially from those expressed in any forward-looking statements made by the company or on the Registrant's behalf, you should not place undue reliance on any forward-looking statements.

All forward-looking statements attributable to the Registrant are expressly qualified in their entirety by the cautionary statements in this "Cautionary Note Regarding Forward-Looking Statements" and the risk factors that are included under Part I, Item 1A – "Risks Factors" in the Registrant's Annual Report on Form 10-K for the fiscal year ended March 31, 2009 and referred to in Part II, Item 1A – "Risk Factors" in the Form 10-Q, as supplemented by the Registrant's subsequent SEC filings.  Further, any forward-looking statement speaks only as of the date on which it is made and the Registrant is under no obligation to update any of the forward-looking statements after the date of this report.

New factors emerge from time-to-time, and it is not possible for the Registrant to predict which factors will arise, when they will arise and/or their effects. In addition, the Registrant cannot assess the impact of each factor on its future business or financial condition or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.


'/>"/>
SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 2013  Recent regulatory and budget challenges have made ... at large pharmaceutical companies to effectively educate doctors and ... of their new products. With the pressure to reduce ... that these "Med Ed" groups find practical, ... address the changes that are transforming the Medical Education ...
(Date:6/18/2013)... , June 18, 2013 Unilife Corporation ... based designer, developer and manufacturer of injectable drug delivery ... website at www.unilife.com . The new site includes ... updates to occur on a regular basis. ... stated, "As an emerging global leader for injectable drug ...
(Date:6/18/2013)... , June 18, 2013  Specialty ... significant breakthrough in Parylene coating technologies: SCS ... the benefits of Parylene with antimicrobial properties ... devices and components. (Logo: ... infections (HAIs) increase and continue to pose ...
Breaking Medicine Technology:Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2Unilife Launches New Corporate Website 2Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2
... All pre-specified subset analyses of progression-free survival,in the ... in,relative risk of disease progression for patients receiving,satraplatin. ... as presence or absence of pain. -- The ... - radiologic,progression and pain progression - were each ...
... ,Abstracts: 2000, 2002 , CHICAGO/DARMSTADT, Germany, June 4, ... today at the American Society of,Clinical Oncology (ASCO) ... cilengitide in patients with newly diagnosed,glioblastoma – a ... highly selective integrin inhibitor targeting the,tumor and its ...
Cached Medicine Technology:Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 2Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 3Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 4Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 5
(Date:6/19/2013)... has been pushed to the brink of extinction but ... the big questions which a Bristol academic addresses in his ... of Medicine at the University of Bristol, has produced the ... with fear: the story of polio explores the experiences of ... of the disease. , According to a review ...
(Date:6/19/2013)... 2013 Ultimate Medical Academy (UMA) participated ... broadcast on WFLA News Channel 8. Since its inaugural ... $84 million for All Children's Hospital in St. Petersburg, ... Years of Miracles," marked the second year UMA volunteered ... worked the phones during the Telethon, which raised a ...
(Date:6/19/2013)... Imprivata ®, a leading global provider of ... OneSign ® leads the single sign-on (SSO) category in ... Services report . CIOs and other healthcare executives iwere ... of its products and the quality of its customer ... integral to their long-term healthcare IT strategy. , ...
(Date:6/19/2013)... June 19, 2013 Maui'd Forever ... dedicated to being an effective and cost effective way ... They have partnered up with Tom Barefoot’s Tours providing ... on most of Hawaii’s activities. , They have just ... can get the lowest prices on their Hawaii activities. ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 The producers of ... dates for Phoenix, Arizona. The city is located in ... Sun”. It has shed its frontier image and become an ... It is the fifth-largest city in the United States with ... industries. It offers residents a low cost-of-living, friendly business environment ...
Breaking Medicine News(10 mins):Health News:Paralysed with fear: The story of polio 2Health News:Ultimate Medical Academy Rallies in Support of All Children's Hospital 2Health News:Ultimate Medical Academy Rallies in Support of All Children's Hospital 3Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3Health News:Maui'd Forever Pleased to Offer Price Guarantee on Hawaii Activities 2Health News:Viewpoints TV Announces June Air Dates for Phoenix, AZ 2
... in the treatment of strokes according to a report released in ... the cord blood could heal strokes almost 80% faster based on ... be worked out and the project itself is in a primitive ... R. Sanberg from the university of South Florida conducted the study. ...
... exclusive to the blessed. The less fortunate are those ... early morning headaches or serious daytime fatigue. Among the ... moderate form is commonly experienced. Sleep apnea is a ... Most individuals may have less severe sleep related breathing ...
... quake-devastated state of,Gujarat in India is now slowly coming ... different news channels and papers are busy increasing the,death ... state government and,the central government are now faced with ... hospitals are crammed with patients and doctors are,desperately needed ...
... have an eating disorder when compared with non-diabetic girls. ... than their prescribed dose of insulin in order to ... onset of diabetes related complications and are associated with ... diabetes could be the risk factor for developing eating ...
... at the just concluded Indian science congress in New Delhi ... combat anemia with iron fortification of crops. Almost 50% of ... anemic in India. While iron supplementation is expensive, fortification of ... anemia in people is fairly cheaper, scientists say. ,This ...
... related tissue experiences ischemia, a state of low oxygen supply ... / Reperfusion (IR) injury occurs during heart attacks. ,Understanding ... to save the damaged tissue and treat heart attack. During ... increases and acts like a common link between the pathways ...
Cached Medicine News:Health News:Doctors needed urgently in Gujarat 2Health News:Doctors needed urgently in Gujarat 3Health News:Doctors needed urgently in Gujarat 4
...
...
...
... The Premier Anterior Cervical Plate System ... screw translation along slots in the ... the distal end of the construct. ... has graft pre-compression features that enable ...
Medicine Products: